The Latest
This Week in HIV Research: Welcome to the Real World
May 27, 2021: Recycling tenofovir in a second-line regimen; real-life two-drug regimen failure rates; jump-starting ART at sexual health clinics; viability of wearable devices in sleep assessment.
Clinical Trial Data Needs to Reflect the Demographics of HIV, Say Activists
A recent analysis conducted by the AIDS Treatment Activists Coalition revealed that, among HIV drug trial participants, data specific to race and sex were dramatically underreported.
HIV Data Bites: Recent Advances in Broadly Neutralizing Antibodies for HIV Prevention
While findings from the high-profile AMP studies have excited scientists, they’re only one of a wide range of bNAb avenues currently being pursued.
Long-Acting ART Is Here. How Do We Make It Work for Our Patients?
Injectable HIV interventions are a game-changing new option for people dealing with pill fatigue, but there are implementation challenges for clinicians to consider.
Broadly Neutralizing Antibodies for HIV? If We Can Do It for COVID ...
David Alain Wohl, M.D., shares his thoughts on broadly neutralizing antibodies for COVID-19—and the extent to which we can hope to see similar developments in HIV.
CROI 2021 Takeaway: Long-Acting Antiretrovirals for HIV Treatment
David Alain Wohl, M.D., talks through new data regarding long-acting antiretroviral therapy for HIV—and touches on the uncertainties clinicians face in incorporating this new treatment method into their practice.
Long-Acting HIV Treatment and PrEP Pipeline Update: So Many Formulations!
CROI 2021 featured new research on a host of long-acting antiretrovirals in development, including less-frequent treatment injections, a weekly pill for HIV treatment, injectable PrEP, vaginal PrEP rings, and PrEP implants.
This Week in HIV Research: Delivering Care Through Uncertainty
Jan. 7, 2021: HIV status and COVID-19 disease severity; associations between tobacco smoking, cancer incidence, viral load, and CD4 count; immune recovery on integrase inhibitors; using smart pill bottles to boost adherence.
NIH Restructures HIV Clinical Trial Networks; AIDS Director Touts Milestones
“You could think of this as ‘who is in and who is out,’ but in reality [restructuring] is more like changing chairs,” said Carl Dieffenbach, Ph.D.
U.S. Waits on Approval of Long-Acting HIV Treatment Cabotegravir and Rilpivirine as European Union Gives the Green Light
The era of once-a-month HIV treatment has begun in the European Union—and it may soon commence in the U.S. as well. Long-acting pre-exposure prophylaxis (PrEP) is also on the horizon.